Cell-targeted mRNA medicines using microRNA signals
microRNA-controlled mRNA therapeutics
This project develops mRNA medicines that are switched off in the wrong cells using natural microRNA signals so they better target immune cells and could improve vaccines and mRNA treatments like those for COVID‑19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11286821 on NIH RePORTER |
What this research studies
mRNA medicines are carried into the body inside lipid particles and can be made in many different cell types, which sometimes causes unwanted responses. The researchers add short microRNA target sequences to the mRNA’s 3' end so the medicine is silenced in cell types that naturally carry that microRNA, steering expression toward desired cells. They will test these designs in lab-grown cells and animal models to see which cell types present the antigen and how that changes immune responses. The aim is to guide future mRNA vaccines and treatments to be safer and more effective for patients.
Who could benefit from this research
Good fit: People who could benefit include those receiving mRNA vaccines or future mRNA-based therapies for viral infections (for example COVID‑19) or who might join clinical trials of cell-targeted mRNA medicines.
Not a fit: Patients with conditions unrelated to mRNA or lipid nanoparticle treatments, or those who cannot receive LNP-based therapies due to allergies or other contraindications, may not benefit from this work.
Why it matters
Potential benefit: If successful, this approach could make mRNA vaccines and therapies more effective and reduce side effects by directing protein expression to the right cell types.
How similar studies have performed: Related preclinical studies have successfully used microRNA target sites to limit transgene expression in specific cell types in animals, but human clinical use of this exact strategy is still early.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Brown, Brian D — Icahn School of Medicine at Mount Sinai
- Study coordinator: Brown, Brian D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.